Skip to main content
. Author manuscript; available in PMC: 2012 Nov 4.
Published in final edited form as: Lancet Oncol. 2011 Mar 22;12(4):377–386. doi: 10.1016/S1470-2045(11)70044-4

Table 2.

Association of the KRAS-variant in 230 patients with triple-negative breast cancer compared with 930 controls from pooled analysis of study groups 1–3

Odds ratio (95% CI) p value
All ages
Univariate analysis
 KRAS variant 1·162 (0·797–1·694) 0·4363
Multivariate analysis
 KRAS variant 1·352 (0·901–2·028) 0·1455
 Age 0·913 (0·942–0·967) <0·0001
 Ethnic origin 2·536 (2·784–5·999) <0·0001
Premenopausal women
Univariate analysis
 KRAS variant 1·879 (1·067–3·310) 0·029
Multivariate analysis
 KRAS variant 2·307 (1·261–4·219) 0·0067
 Age 0·913 (0·871–0·956) 0·0001
 Ethnic origin 2·536 (1·582–4·067) 0·0001

Age, ethnic origin, menopausal status, and study site were adjusted in a logistic regression model. G/G phenotype occurs in less than 5% of cases and controls and was combined with the G/T phenotype.